SNOA — Sonoma Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapNeutral

Annual income statement for Sonoma Pharmaceuticals, fiscal year end - March 31st, USD millions except per share, conversion factor applied.

	R2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	17.9	18.6	12.6	13.3	12.7
Cost of Revenue
Gross Profit	8.12	6.78	4.21	4.71	4.75
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses	25.3	22.1	17.8	17.8	17.4
Operating Profit	-7.39	-3.45	-5.16	-4.57	-4.7
Total Net Non Operating Interest Income / Expense
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-3.54	-3.9	-5.42	-5.18	-5.03
Provision for Income Taxes
Net Income After Taxes	-3.57	-4.62	-5.09	-5.15	-4.83
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-3.31	-3.95	-5.09	-5.15	-4.83
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-3.31	-3.95	-5.09	-5.15	-4.83
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-79.8	-45.7	-41.6	-29.5	-10.6